文献速递脑血管病外科

Pipeline栓塞装置治疗颅内动脉瘤:1000例动脉瘤单中心注册研究长期结局

Pipeline Embolization Devices for the Treatment of Intracranial Aneurysms, Single-Center Registry: Long-Term Angiographic and Clinical Outcomes from 1000 Aneurysms.
PubMed 文献 · Neurosurgery · 2021-01-01

PEDESTRIAN注册研究回顾性纳入2006年3月至2019年7月835例复杂颅内动脉瘤患者共1000个动脉瘤,均使用Pipeline栓塞装置治疗。随访造影显示动脉瘤完全闭塞率随时间提高:12个月为75.8%,2至4年为92.9%,5年以上为96.4%。术后96.2%患者改良Rankin量表评分稳定或改善,总体重大并发症与神经性死亡率为5.8%。

要点

  • PED治疗复杂颅内动脉瘤的长期完全闭塞率高,5年以上达96.4%。
  • 术后功能结局稳定或改善者占96.2%,5年以上达99.1%。
  • 总体重大并发症与神经性死亡率为5.8%。

核心结论

  • PED治疗颅内动脉瘤可获得较高的长期完全闭塞率、稳定或改善的功能结局以及较低的并发症和死亡率。
  • 随着随访时间延长,临床与造影结局持续改善,提示该血管内治疗安全有效。

研究设计与样本

  • PEDESTRIAN注册研究为回顾性单中心注册研究,纳入2006年3月至2019年7月接受PED治疗的复杂颅内动脉瘤患者。
  • 共纳入835例患者(平均年龄55.9±14.7岁,女性占80.0%)和1000个动脉瘤,排除急性蛛网膜下腔出血者。
  • 共置入1214枚PED,85.1%的患者(776个动脉瘤)获得造影随访,平均随访24.6±25.0个月。

主要发现

  • 动脉瘤大小分布为小型(≤10 mm)占64.6%、大型(11-24 mm)占25.6%、巨大型(≥25 mm)占9.8%。
  • 完全闭塞率在12个月为75.8%,2至4年为92.9%,5年以上为96.4%。
  • 术后改良Rankin量表评分稳定或改善者占96.2%,5年以上为99.1%。
  • 总体重大并发症与神经性死亡率为5.8%。

临床怎么用

  • 对复杂颅内动脉瘤(含解剖条件不佳或既往治疗后复发者)可考虑使用PED行血管内治疗。
  • 术后需按3至6个月、12个月及此后每年进行临床与影像随访,以评估闭塞进程与功能结局。

局限性

  • 本研究为单中心回顾性注册研究,可能存在选择偏倚与随访不完整。
  • 造影随访仅覆盖85.1%的患者和776个动脉瘤,平均随访时间差异较大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prospective studies have established the safety and efficacy of the PipelineTM Embolization Device (PED; Medtronic) for treatment of intracranial aneurysms (IA). OBJECTIVE: To investigate long-term outcomes from the Pipeline Embolization Devices for the Treatment of Intracranial Aneurysms (PEDESTRIAN) Registry. METHODS: The PEDESTRIAN Registry data were retrospectively reviewed, which included patients (March 2006 to July 2019) with complex IAs treated with PED. Patients with unfavorable anatomy and/or recurrence following previous treatment were included and excluded those with acute subarachnoid hemorrhage. The primary angiographic endpoint was complete occlusion and long-term stability. Clinical and radiological follow-up was performed at 3 to 6 mo, 12 mo, and yearly thereafter. RESULTS: A total of 835 patients (mean age 55.9 ± 14.7 yr; 80.0% female) with 1000 aneurysms were included. Aneurysms varied in size: 64.6% were small (≤10 mm), 25.6% were large (11-24 mm), and 9.8% were giant (≥25 mm). A total of 1214 PEDs were deployed. Follow-up angiography was available for 85.1% of patients with 776 aneurysms at 24.6 ± 25.0 mo (mean). Complete occlusion was demonstrated in 75.8% of aneurysms at 12 mo, 92.9% at 2 to 4 yr, and 96.4% at >5 yr. During the postprocedural period, modified Rankin Scale scores remained stable or improved in 96.2% of patients, with stability or improvement in 99.1% of patients >5 yr. The overall major morbidity and neurological mortality rate was 5.8%. CONCLUSION: This study demonstrated high rates of long-term complete aneurysm occlusion, stable or improved functional outcomes, and low rates of complications and mortality. Clinical and angiographic outcomes improved over long-term follow-up, demonstrating that endovascular treatment of IA with PED is safe and effective.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Lylyk I, Scrivano E, Lundquist J, et al. Pipeline Embolization Devices for the Treatment of Intracranial Aneurysms, Single-Center Registry: Long-Term Angiographic and Clinical Outcomes from 1000 Aneurysms. Neurosurgery. 2021. PMID: 34098575. doi:10.1093/neuros/nyab183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。